Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oblimersen Sodium with Carboplatin and Etoposide in Extensive Stage Small Cell Lung Cancer
NCT00042978Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2003
- Primary completion
- May 2005
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oblimersen in small cell lung cancer (SCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Percentage of patients who live longer than 12 months. Started Apr 2003; status: completed.
02
Drugs
oblimersen
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00042978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042978.